Check the time stamp on this data. Updated AI-Generated Signals for Collegium Pharmaceutical Inc. (COLL) available here: COLL ...

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have been given an average rating of “Moderate Buy” by the five research firms that are covering the company, MarketBeat ...

HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $50.

In December 2024, the collegium met candidates for high court judgeships in Rajasthan, Allahabad and Bombay to assess their suitability for elevation It will be a working holiday for the top three ...

In an exclusive conversation on a range of issues with CNN-News18 on Saturday, he said that the collegium system of judges’ appointments needs improvement to provide equal opportunity for all. “Being ...

Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy. Analyst Price Forecast Suggests 29.26% Upside As of December ...

Collegium's 2025 guidance surpasses estimates with projected sales of $735-$750M and adjusted EBITDA of $435-$450M. Analyst highlights growth potential from Jornay PM and strong pain portfolio ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue.

The decision was taken by the Supreme Court collegium at a meeting held on Tuesday (January 7, 2025). The Collegium, however, is yet to recommend the name for the new Chief Justice for Telangana ...